Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...

French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Secondary Progressive Multiple Sclerosis (SPMS).

The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary ...

Let’s roll. An oral treatment developed by the French pharma giant Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder that causes the body ...

Sanofi SA will invest around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing, its biggest single investment in China to date and part of a broader push to boost ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...